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Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative 
radiotherapy (RT) or concurrent chemoradiotherapy.
Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic 
factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, 
treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival 
was analyzed in 35 patients.
Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. 
Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant 
failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up 
at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. 
In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor 
prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but 
the differences were not significant statistically.
Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic 
factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be 
considered for old age ≥70 years.
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Introduction
Vulvar cancer is a relatively uncommon disease, accounting for 
about 5% of all gynecological malignancies [1]. According to 
United States’ statistics from the Surveillance, Epidemiology, 
and End Results registries, nearly 90% of patients with vulvar 
cancer are diagnosed at an early stage, whereas advanced 
disease predominantly occurs in older patients, with poor 
treatment outcomes [2]. Traditionally, surgical management has 
played a major role in the curative treatment for vulvar cancer, 
and radiotherapy (RT) has been used as an adjuvant therapy or 
in the palliative context. Disease control of the inguinofemoral 
region is regarded as an important approach to the treatment 
of vulvar cancer, based on the report of the Gynecologic 
Oncology Group (GOG), which assigns an extremely important 
prognostic value to groin lymph node (LN) metastasis 
[3]. Although radical vulvectomy with inguinofemoral 
lymphadenectomy with or without pelvic nodal area, produces 
favorable oncological outcomes as groin recurrence rates of 
<10% [4-6], it leaves the patient with significant postoperative 
morbidity, including psychological problems, wound disruption, 
lymphedema, or sexual dysfunction [7-9]. A high mortality 
rate (up to 20%) has been reported in cases of advanced-
stage disease following surgical procedures [10]. The survival 
outcomes after definitive RT with chemotherapy vary from 
46.2% to 65.0% [11-13]. Although the probability of tumor 
control by RT in patients with small tumors is similar to that 
for surgery, the results have generally been poor in terms of 
both the local control rate and the treatment-related toxicity 
in patients with stages III–IV vulvar cancer [14]. In recent 
phase II GOG studies of concurrent chemoradiotherapy 
(CCRT), clinical complete remission was achieved in 47.9% 
to 63.8% of patients and pathologic complete remission in 
31.0% to 50.0% [15,16]. However, in many cases, patients 
require tumor resection because the tumor has a less-than-
complete response to CCRT, and complication rates are higher 
and morbidity significantly greater in those cases [17]. Given 
the rarity of the disease, few randomized trials have compared 
the efficacy of surgery with RT as the definitive tools for its 
treatment. With this background, we evaluated the clinical 
outcomes and prognostic factors of patients with vulvar 
cancer treated primarily with RT. The study was a retrospective 
review of the medical records of 7 institutions in Korea.
Materials and Methods
The records of 118 patients with carcinoma of the vulva, who 
were treated at 7 institutions in Korea between 1998 and 
2011, were retrospectively evaluated. Patients were included 
if they had biopsy-proven squamous cell carcinoma or 
adenocarcinoma of the vulva and had received RT or CCRT 
with curative intent. Patients were excluded from the analysis 
Table 1. Patient demographics (n = 56)
Parameter Value
Age (yr), median (range)
Smoking history
   Yes
   No
History of cervix cancer
   Yes
   No
Pathology
   Squamous cell carcinoma
   Adenocarcinoma
T classification
   1
   2
   3
N classification
   0
   1
   2
FIGO stage
   I
   II
   III
      IIIA
      IIIB
      IIIC
   IV
      IVA
      IVB
Tumor size (cm)
   <3
   ≥3
Inguinal node (+)
   Yes
   No
Pelvic lymph node (+) 
   Yes
   No
HPV status
   Positive
   Negative
   Unknown
 71 (28–90)
 
4 (7)
52 (93)
 
2 (4)
54 (96)
 
55 (98)
1 (2)
 
20 (36)
22 (39)
14 (25)
 
24 (43)
12 (21)
20 (36)
 
8 (14)
8 (14)
20 (36)
9 (16)
10 (18)
1 (2)
20 (36)
10 (18)
10 (18)
 
30 (54)
26 (36)
 
32 (57)
24 (43)
 
10 (18)
46 (82)
 
15 (27)
20 (36)
21 (37)
Values are presented as median (range) or number (%).
FIGO, International Federation of Gynecology and Obstetrics; HPV, 
human papillomavirus.
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if they had as follows: 1) histological evidence of melanoma, 
basal cell carcinoma, or adenoid cystic carcinoma; 2) distant 
metastasis, other than pelvic LN metastasis; 3) had received 
neoadjuvant chemotherapy; or 4) had undergone radical 
vulvectomy. Ultimately, 56 patients were included in the 
analysis.
1. Patient demographics
The patients’ demographic data are shown in Table 1. The 
median age was 71 years (range, 28 to 90 years) and the 
majority of patients (98%) had squamous cell carcinoma. All 
patients were staged with the surgical pathological staging 
system for vulvar cancer of the International Federation 
of Gynecology and Obstetrics (FIGO), established in 2009. 
Fourteen patients (25%) had a clinical T3 classification and 
26 (36%) had tumors ≥3 cm. Of the 56 patients analyzed, 32 
(57%) had inguinal LN metastasis and 10 (18%) had pelvic 
LN metastasis. Eight patients (14%) had FIGO stage I disease, 
eight (14%) stage II, 20 (36%) stage III, and 20 (36%) stage IV.
2. Pretreatment evaluation and treatment modalities
All patients underwent physical and pelvic examinations, 
routine laboratory testing, chest radiography, colposcopy, 
cystoscopy, and sigmoidoscopy. When advanced-stage disease 
was diagnosed, further evaluation with magnetic resonance 
imaging (MRI) or positron emission tomography-computed 
tomography was performed.
Of all the patients, 23 (41%) received CCRT and 33 (59%) 
only RT (Table 2). The selection of the treatment modality 
was at the discretion of the treating physicians. The general 
schema for CCRT involved weekly cisplatin or cisplatin plus 
5-fluorouracil concurrently with external-beam radiation. The 
radiation fraction size was generally 1.8 to 2 Gy, delivered once 
a day, with a median total dose of 65 Gy (range, 45 to 130 Gy). 
The radiation technique and dose were individualized for each 
patient, depending on the site and volume of the tumor. The 
majority of patients (91%) received two-dimensional RT (2D-
RT) or three-dimensional conformal RT (3D-CRT). Until the 
late 1990s 2D-RT was predominantly used and 3D-CRT was 
used from early 2000. In terms of the extent of the RT field, 42 
patients (75%) received RT to the primary vulva, both inguinal 
LNs, and the whole pelvis. A boost to the primary vulvar site 
with brachytherapy (n = 8) or external-beam RT (n = 44) was 
applied in 52 (93%) patients. The median overall treatment 
time was 57 days (range, 36 to 111 days).
3. Human papillomavirus (HPV) status
Genomic deoxyribonucleic acid (DNA) was extracted from the 
paraffin-embedded tissue sections or frozen tissues using 
the QIAamp DNA mini kit (Digene Corp., Gaithersburg, MD, 
USA). When the cell samples were obtained by scraping the 
vulvar lesions, the brush containing the cellular material was 
placed directly in a vial containing PreservCyt solution (Digene 
Corp.) before testing. The HPV DNA titer was measured with 
a commercially available second-generation hybrid capture 
microplate-based HPV DNA test (HC2 test, Digene Corp.). The 
HC2 test uses an RNA probe mixture of 13 high-risk HPV types 
(HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68). The relative light unit (RLU)/cutoff ratios were calculated 
as the ratio of the specimen luminescence to the luminescence 
of the 1.0 pg/mL HPV 16 cutoff standard. RLU/cutoff ≥1.0 
was considered positive, according to the manufacturer’s 
recommendation (Digene reference no. 5199-1220).
4. Statistics
Acute toxicity, measured from the initiation of treatment to 
three months after RT or CCRT, was assessed with the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (v4.0) [18], from the medical records of the patients 
at each institution. Late toxicity was graded according to the 
Radiation Therapy Oncology Group Late Morbidity Scoring 
Table 2. Treatment-related characteristics (n = 56)
Parameter Value
Modality
   RT alone
   CCRT
RT field
   Vulva only
   Vulva + inguinal
   Vulva + inguinal + whole pelvis
   Whole pelvis
RT dose to vulva (Gy)
   <65
   ≥65
Overall treatment time (day)
   <60
   ≥60
RT technique
   2D-RT
   3D-CRT
   IMRT
 
33 (59)
23 (41)
 
3 (5)
8 (14)
42 (75)
3 (5)
65 (45–130)
21 (38)
35 (63)
57 (36–111)
34 (61)
22 (39)
 
36 (64)
15 (27)
5 (9)
Values are presented as number (%) or median (range).
RT, radiotherapy; CCRT, concurrent chemoradiotherapy; 2D-RT, 
two-dimensional radiotherapy; 3D-CRT, three-dimensional con-
formal radiotherapy; IMRT, intensity-modulated radiotherapy.
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Criteria [19]. A complete response was defined as the complete 
clinical or radiological disappearance of gross disease, based 
on a physical examination and an MRI scan, which were 
performed three months after the completion of treatment. 
Local failure was defined as either persistent disease at 
three months after the completion of treatment or any local 
recurrence. Regional failure was defined as either persistent 
groin (inguinofemoral) disease at three months after the 
completion of treatment or any groin nodal recurrence. Distant 
failure was defined as the development of any distant disease 
including pelvic nodal failure irrespective of RT field. Disease-
free survival (DFS) was calculated from the start of treatment 
to the date of locoregional or distant failure or death from 
any cause. Any recurrence or relapse, or death from any cause, 
was regarded as an event. Overall survival (OS) was calculated 
from the start of treatment to the date of death or the last 
follow-up. The 5-year actuarial rates of OS and DFS were 
analyzed by Kaplan-Meier method. Univariate analyses of 
prognostic factors for OS and DFS were performed with the 
log-rank test. Factors independently associated with OS or 
DFS were identified with a multivariate analysis using the Cox 
proportional hazards regression model. The p-values of less 
than 0.05 were considered significant. All statistical analyses 
were performed with SPSS ver. 19.0 (IBM, Armonk, NY, USA).
Results
The median follow-up period was 2.8 years (range, 0.3 to 18.9 
years) for all patients. Of the 56 patients, 29 (51.8%) were alive 
at follow-up, 15 (26.8%) had died from vulvar cancer itself or 
treatment-related complications, and 11 (19.6%) had died from 
age-related or other causes. One patient was lost to follow-up 
after the first follow-up schedule.
1. Patterns of treatment failure
In total, 21 patients (37.5%) experienced treatment failure (Fig. 
1). Local failure was observed in 15 patients (27%): 9 (16%) 
with local failure only, 3 (5%) with locoregional failure, 2 (4%) 
with local and distant failure, and 1 (2%) with locoregional 
and distant failure. Of 56 patients, 7 (13%) showed persistent 
disease at the first follow-up at 2 months and all but one died 
within a year after completing RT. Distant failure was identified 
in 9 patients (16%): 4 patients (7%) had distant failure only (2 
lung, 1 pelvic failure outside the RT field, 1 unknown due to 
Median follow-up 2.8 years (range, 0.3-19.0)
Local failure
(n = 15, 27%)
Regional failure
(n = 6, 11%)
Distant failure
(n = 9, 16%)
9
0 4
1
23
2
Fig. 1. Patterns of treatment failure.
Fig. 2. Five-year survival rates: (A) overall survival (OS), (B) disease-free survival (DFS).
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incomplete data), 5 (9%) had distant failure with either local or 
regional failure or both of them (1 lung, 1 pelvic bone, 2 para-
aortic LN, and 1 pelvic failure outside the RT field). No patient 
had regional failure only.
2. Survival and prognostic factors
The 5-year OS and DFS rates were 51.6% and 44.0%, 
respectively (Fig. 2). In a univariate analysis (Table 3), age was 
the strongest prognostic factor for OS (p = 0.009) and DFS (p 
= 0.008). Neither the FIGO stage, inguinal LN metastasis, nor 
pelvic LN metastasis was a prognostic factor for OS or DFS, 
whereas tumor size ≥3 cm was a prognostic factor for OS 
(p = 0.043) and DFS (p = 0.019). A radiation dose of ≥65 Gy 
to the gross tumor volume appeared to be associated with a 
higher failure rate (Table 3). Since it was interpreted that this 
finding was resulted from the use of a higher radiation dose 
in patients whose interim response was poor, a radiation dose 
of ≥65 Gy was not included in multivariate analysis. When 
age, size of the primary lesion, inguinal LN metastasis, pelvic 
LN metastasis, and treatment modality were considered in the 
multivariate analysis, the only prognostic factor for OS and 
DFS was age (p-value, 0.048 and 0.032, respectively), whereas 
tumor size ≥3 cm was a poor prognostic factor for DFS only (p 
= 0.040) (Table 4).
3. Treatment-related toxicity
The most common acute toxicity affected the skin (Table 
5). Grade 3 acute skin toxicity was observed in 12 patients 
(21%). Seven patients (13%) experienced grade 2 acute 
gastrointestinal toxicity, which was transient and controlled 
with supportive care, and one patient suffered grade 3 acute 
gastrointestinal toxicity. Grade 2 acute genitourinary toxicity 
was observed in 10 patients (18%). Only one patient suffered 
grade 3 acute hematological toxicity.
Table 3. Univariate analysis of prognostic factors for overall and disease-free survival (n = 56)
Variable
OS DFS
5-yr (%) p-value 5-yr (%) p-value
Age (yr)
   <70 vs. ≥70
FIGO stage
   I–II vs. III–IV
Tumor size (cm)
   <3 vs. ≥3 
T classification
   1–2 vs. 3
Inguinal LN (+)
   No vs. Yes
Pelvic LN (+)
   No vs. Yes
Treatment modality
   RT vs. CCRT
RT field
   Vulva + inguinal vs. + WPa)
RT technique
   2D-RT vs. 3D-CRT, IMRT
RT dose
   <65 Gy vs. ≥65 Gy
Overall treatment time (day)
   <60 vs. ≥60
HPV (n = 35)
   Positive vs. Negative
 
70 vs. 39
 
58 vs. 49
 
66 vs. 36
 
55 vs. 42
 
56 vs. 50
 
58 vs. 21
 
54 vs. 46
 
51 vs. 53
 
56 vs. 45
 
70 vs 42
 
54 vs. 50
 
61 vs. 47
 
0.009*
 
0.728
 
0.043*
 
0.948
 
0.949
 
0.156
 
0.691
 
0.810
 
0.517
 
 0.018*
 
0.485
 
0.142
 
61 vs. 32
 
53 vs. 40
 
59 vs. 30
 
45 vs. 34
 
53 vs. 38
 
47 vs. 31
 
48 vs. 33
 
40 vs. 45
 
53 vs. 28
 
62 vs 34
 
42 vs. 48
 
71 vs. 42
 
0.008*
 
0.538
 
0.019*
 
0.980
 
0.500
 
0.233
 
0.939
 
0.605
 
0.052
 
 0.027*
 
0.356
 
0.215
OS, overall survival; DFS, disease-free survival; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; RT, radio-
therapy; CCRT, concurrent chemoradiotherapy; 2D-RT, two-dimensional radiotherapy; 3D-CRT, three-dimensional conformal radiothera-
py; IMRT, intensity-modulated radiotherapy; HPV, human papillomavirus.
a)+ WP = vulva + inguinal + whole pelvis.
*Statistically significant at p < 0.05.
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4. Subanalysis of tumor HPV status and survival
HPV-positive vulvar cancer was more common in younger 
patients (median age was 64.5 years in HPV-positive patients 
and 75 years in HPV-negative patients). Nine (60%) of the 
15 HPV-positive patients were <70 years old (Pearson χ2, p = 
0.036). The HPV-positive patients tended to have better 5-year 
OS and DFS, but these trends were not significant in the 
univariate analysis (all p > 0.05) (Fig. 3).
Discussion and Conclusion
Because the disease is rare and surgery is the mainstay 
treatment for early vulvar cancer, limited data are available on 
the outcomes of primary RT for vulvar cancer. Many published 
studies have included the results for heterogeneous groups 
of patients, with disease severity extending from FIGO stage I 
to stage IV, so the treatment outcomes reported tend to vary. 
Tans et al. [13] suggested that the 4-year actuarial rates for 
locoregional control and OS were 75% and 65%, respectively, 
in locally advanced vulvar carcinoma. In a comparison of 
primary surgery and chemoradiation for FIGO stage III–IV 
vulvar cancer, patients treated with definitive chemoradiation 
showed an OS rate of 75% [14]. In contrast, Han et al. [11] 
reported 5-year rates for relapse-free survival and OS of 43% 
and 54%, respectively, in 14 patients who received primary 
chemoradiation therapy. Lee et al. [12] reported 5-year DFS and 
OS rates of 42.2% and 46.2%, respectively, in heterogeneous 
patients treated with primary or adjuvant RT with or without 
concomitant chemotherapy.
Our study shows that the general treatment outcomes of 
vulvar cancer are poor, with 5-year OS, and DFS rates of 51.6% 
and 44.0%, respectively. The main cause of treatment failure 
was local failure, and a substantial amount of persistent local 
disease was noted at the end of RT in 13% (7/56) of patients. 
Table 4. Multivariate analysis for OS and DFS (n = 56)
Variable
OS DFS
HR p-value HR p-value
Age (yr)
   <70 vs. ≥70
Tumor size (cm)
   <3 vs. ≥3
Inguinal LN (+)
   No vs. Yes
Pelvic LN (+)
   No vs. Yes
Treatment modality
   RT vs. CCRT
 
2.5
 
1.9
 
0.9
 
1.9
 
10.8
 
0.048*
 
0.106
 
0.774
 
0.204
 
0.669
 
2.4
 
2.2
 
1.2
 
1.8
 
0.9
 
0.032*
 
0.040*
 
0.722
 
0.230
 
0.857
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; 
LN, lymph node; RT, radiotherapy; CCRT, concurrent chemoradio-
therapy.
*Statistically significant at p < 0.05.
Table 5. Acute toxicity related to radiotherapy for vulvar carcinoma 
(n = 56)
CTCAE
Incidence, no. (%)
Skin GI GU
Grade 1
Grade 2
Grade 3
NA
14 (25)
18 (32)
12 (21)
1 (2)
10 (18)
7 (13)
1 (2)
1 (2)
20 (36)
10 (18)
0 (0)
1 (2)
CTCAE, Common Terminology Criteria for Adverse Events v4.0; GI, 
gastrointestinal; GU, genitourinary; NA, not assessed.
Fig. 3. Survival rates according to human papillomavirus (HPV) status: (A) overall survival (OS) and (B) disease-free survival (DFS).
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One reason for the considerably higher local failure rate was 
the RT technique used. These patients were treated with an RT 
technique that evolved from 2D-RT to intensity-modulated 
RT (IMRT) between 1989 and 2012. It is difficult to deliver 
a homogeneous radiation dose to the target area, which 
includes the vulvar, the inguinofemoral LNs, and even the 
pelvic LNs, with 2D-RT or 3D-CRT. Therefore, techniques such 
as IMRT, which can deliver different doses to the primary site 
and the regional LNs, are required. According to the report of 
Beriwal et al. [20], the best dose distribution for the treatment 
of vulvar carcinoma can be achieved with IMRT. They reported 
favorable clinical outcomes, with complete clinical responses, 
in 74% of patients, complete pathological responses in 64%, 
and a 2-year disease-specific survival rate of 75%, with no 
grade 3 acute or late morbidity when preoperative CCRT was 
performed with IMRT in patients with FIGO stage II–IVA vulvar 
cancer [21].
It has been observed that there are two different etiologic 
pathogenesis in vulvar carcinogenesis [22,23]. The first is often 
observed in younger patients less than 50 years old who more 
frequently smoke and are at higher risk for HPV infection and 
whose invasive cancers are commonly associated with vulvar 
intraepithelial neoplasia (VIN). The second is seen in elderly 
patients whose disease may be unrelated to HPV infection or 
VIN but lichen sclerosis and chronic inflammation are common. 
The present study also showed that HPV-positive vulvar cancer 
was more common in younger patients (median age was 64.5 
years in HPV-positive patients and 75 years in HPV-negative 
patients) although it was not in less than 50 years old. It has 
not been clearly investigated for correlation between HPV 
status and survival outcome in vulvar cancer. Alonso et al. [24] 
reported that no differences were seen between HPV positive 
and HPV negative tumors in terms of 5-year DFS (39.8% vs. 
49.8%, p = 0.831) and OS (67.2% vs. 71.4%, p = 0.791). Pinto 
et al. [25] also suggested that high-risk HPV DNA was not 
associated with prognostic significance for death (hazard 
ratio, 0.9) and recurrence (hazard ratio, 0.8) in invasive vulvar 
carcinoma following radical vulvectomy. We also investigated 
correlation between HPV status and survival outcome but no 
statistical difference was shown for OS, DFS according to HPV 
status. In this study, however, the information on HPV status 
was limited to a subset of patients and differences in the 
prognoses of patients with different etiologies (HPV-related 
or chronic-inflammation-related carcinogenesis) could not 
be determined. In the future, more investigation would be 
necessary for the prognosis according to HPV status.
Compared with the acute skin grade 3 toxicity rate of 21% 
observed in the current study, IMRT seems to entail a lower 
risk of skin toxicity, with a good clinical response. In our study, 
IMRT was used in only five patients (8.9%), two of whom 
treated with IMRT alone suffered local recurrence, leading to 
their deaths whereas the remaining 3 patients were treated 
with CCRT (concomitant platinum-based chemotherapy with 
IMRT). A previous study showed that chemoradiation achieved 
a better local control rate and survival rate than RT alone 
when used as the primary treatment for vulvar cancer [11], so 
concomitant chemotherapy with RT should be considered to 
improve the local control rate and perhaps the survival rate.
One of the limitations of our study was that we could 
not collect accurate data for the tumor response during or 
at the end of RT. In many cases, the medical records did not 
determine whether the tumor had responded completely 
on image/physical examination. A higher radiation dose is 
associated with a better tumor control, however a radiation 
dose of ≥65 Gy to the gross tumor volume appeared to be 
associated with a higher failure rate in this study. We interpret 
this finding as resulting from the use of a higher radiation 
dose in patients whose interim response was poor. However, 
we have to admit that the limitation of this study made it 
conjecture. In the future, further prospective study would be 
necessary to investigate the correlation between radiation dose 
and tumor response. Secondly, we are unable to report any late 
toxicity in this study because the medical records for many of 
these patients were unfaithful. Two patients who received over 
100 Gy radiation to the primary site could not be assessed for 
late toxicity because they were lost to follow-up. Considering 
that insufficient fracture was reported from up to 45% of the 
patients after pelvic RT in cervical cancer [26], several patients 
in our study might also suffered from insufficient fracture 
after treatment.
Our data do not show that the survival rates differed 
according to the clinical stage of the disease, but only age and 
tumor size most effectively predicted the survival outcomes. 
We retrospectively investigated the clinical outcomes and 
prognostic factors of patients with vulvar cancer treated 
primarily with RT. The median age was 71 years (range, 28 to 
90 years). Of sixteen patients with stage I and II disease, 9 (56%) 
were older than 70 years. In general, medically inoperable 
patients with early stage disease might be referred to receive 
RT, consequently, which had resulted in poor outcome in those 
patients. A substantial amount of persistent local disease was 
also noted at the end of RT in 13% (7/56) of patients, who 
were all older than 70 years. It could explain why surgical 
consolidation therapy was not considered in those patients. 
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In the future, further investigation would be necessary to 
determine which could be the treatment of choice for old age 
group.
In conclusion, this study suggests that a tumor size ≥3 
cm is associated with a negative clinical outcome in DFS in 
patients with treated with curative RT. However, age ≥70 years 
indicates the most significant poor prognosis for OS and DFS. 
In the future, further study would be necessary to determine 
which treatment should be considered for old age group and 
more investigations are needed to define the prognoses of old 
age group with different etiologies according to HPV-related 
or chronic-inflammation-related carcinogenesis.
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